What is Lixte Biotechnology Holdings Financial Strength?
Lixte Biotechnology Holdings has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Lixte Biotechnology Holdings Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Lixte Biotechnology Holdings did not have earnings to cover the interest expense.
As of today, Lixte Biotechnology Holdings's Altman Z-Score is 0.00.
Competitive Comparison of Lixte Biotechnology Holdings's Financial Strength
For the Biotechnology subindustry, Lixte Biotechnology Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lixte Biotechnology Holdings's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Financial Strength distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's Financial Strength falls into.
Lixte Biotechnology Holdings Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Lixte Biotechnology Holdings's Interest Expense for the
months ended in Mar. 2024 was $-0.01 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-0.97 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
Lixte Biotechnology Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is
| Lixte Biotechnology Holdings did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Lixte Biotechnology Holdings's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Lixte Biotechnology Holdings has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description
Traded in Other Exchanges
N/A
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Executives
| Rene Bernards |
director |
KONINGSVAREN 37, ABCOUDE P7 1391AD |
| Van Der Baan Bastiaan Jeroen |
director |
HOGEWEG 4-H, AMSTERDAM P7 1098CB |
| Eric Forman |
10 percent owner |
117 E. 29TH ST., APT. 5A, NEW YORK NY 10016 |
| Regina Brown |
director |
248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733 |
| Glenn Krinsky |
10 percent owner |
C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067 |
| Yun Yen |
director |
1301 OAKLAWN ROAD, ARCADIA CA 91006 |
| Robert Greenberg |
10 percent owner |
SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266 |
| Gil Schwartzberg |
10 percent owner |
269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212 |
| Philip F Palmedo |
director |
1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067 |
| John S Kovach |
director, 10 percent owner, officer: Pres., CFO & Secty |
1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067 |
| Stephen J. Forman |
director |
248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733 |
| Hung Tak Ho |
10 percent owner |
MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000 |
| Robert N Weingarten |
officer: Vice President and CFO |
5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367 |
| James Miser |
officer: Chief Medical Officer |
680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101 |
| Jane Merrill Riggs |
10 percent owner |
4852 SAINT ANDRES AVENUE, LA VERNE CA 91750 |
Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIXT has been successfully added to your